CN106074585A - Ginsenoside Rb1 and Rd combination and preparation treatment photoreceptor cell death relevant disease medicine in application - Google Patents
Ginsenoside Rb1 and Rd combination and preparation treatment photoreceptor cell death relevant disease medicine in application Download PDFInfo
- Publication number
- CN106074585A CN106074585A CN201610494685.9A CN201610494685A CN106074585A CN 106074585 A CN106074585 A CN 106074585A CN 201610494685 A CN201610494685 A CN 201610494685A CN 106074585 A CN106074585 A CN 106074585A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- pharmaceutical composition
- retinal
- degeneration
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to ginsenoside Rb1 and the Rd combination application in preparation treatment Retinal degeneration medicine.The present invention uses the mouse model of retina photodamage, simulate the Common key pathology link in multiple Retinal degeneration generating process, research ginsenoside Rb1 and the Rd combination intervention effect to retina photodamage mouse model, result shows that this drug regimen can maintain outer nuclear layer form, effectively prevent outer nuclear layer degeneration from damaging, prevent outer nuclear layer thickness from reducing, suppression photoreceptor cell is dead, antagonism retinal pigment epithelium and photoreceptor cell oxidative stress, effectively suppression retina injury related immune inflammatory reaction, significantly improve Retinal degeneration.Therefore ginsenoside Rb1 and Rd combination can be used for the preparation treatment multiple Retinal degeneration medicine including age-related macular degeneration, retinitis pigmentosa, Stargardt disease, cone rod cell malnutrition, diabetic retinopathy etc..
Description
Technical field
The present invention relates to pharmaceutical technology field, specifically, relate to ginsenoside Rb1 and Rd combination in preparation treatment with light
Receptor cell is dead, retinal pigment epithelium and photoreceptor cell oxidative stress be central pathological include age phase
Closing property degeneration of macula, Stargardt disease, the cone-rod cell malnutrition, retinitis pigmentosa and diabetic retinopathy
Become the application in interior Retinal degeneration medicine.
Background technology
Retina degenerative disease be one group with on retinal light injury photoreceptor oxidative stress, death and retinal pigment
Chrotoplast oxidative stress is that central pathological changes, and can cause the retinopathy that visual disorder is the most blind, and it includes that the age is correlated with
Property degeneration of macula, Stargardt be sick, the cone-rod cell malnutrition, retinitis pigmentosa etc..Additionally, photoreceptor is thin
Born of the same parents' over oxidation stress be the important early stage pathology link that diabetic retinopathy occurs.For Retina death, regard
The treatment of retinal pigment epithelial cell and the photoreceptor cell oxidative stress generation to above-mentioned associated retinal degeneration
Effective intervention effect is played in development.
Age-related macular degeneration is modal serious harm the vision health even view of blinding in world wide
One of main Types of film degeneration.China's Epidemiological study shows, within more than 50 years old, population ages's Macular becomes
The prevalence nearly 15.5% of property.Aged tendency of population directly results in the prevalence of age-related macular degeneration to be increased year by year, structure
Become serious social public health problem.The clinical manifestation of age-related macular degeneration is generally divided into " dryness " and " moist " two
Type.Dry age degeneration of macula, multiple is born in more than 50 years old.Vision shows as slow Progressive symmetric erythrokeratodermia and declines or metamorphopsia,
Account for age-related macular degeneration morbidity more than 90%, there is no effective medicine at present.The cone, rod cell nutrition are not
Good is one group of heredopathia, the gene mutation such as ABCA4 cause, with visual deterioration, nyctalopia, constriction of visual field, photoreceptor function not
Good for principal character, there is no effective medicine at present.Retinitis pigmentosa is a kind of carrying out taken as the leading factor with inherited genetic factors
Property, the Retinal degeneration of dystrophic, relate to gene diversity, even same gene can show as in different patients
Different sudden changes.Mainly show as chronic progressive external visual field disappearance, ablepsia, nyctalopia, electroretinogram exception, visual disorder very
To blind, there is no effective medicine at present.Diabetes are one of great metabolic diseases of hyperglycemia initiation.End 2012
JIUYUE, in worldwide, the people of about 300,000,000 4 thousand 7 million suffers from diabetes.Diabetes have become and have been only second to cardiovascular disease and swollen
The third-largest noninfectious of tumor.Diabetic retinopathy is one most commonly seen in diabetic complication, at glycosuria
The early stage of sick process i.e. may occur in which, is to cause blind first factor in worldwide.At diabetic retinopathy
Sickness rate gradually rises with the lengthening of diabetic duration, and within more than 10 years, person's sickness rate increases to 69%-90%.The course of disease more than 15 years
Diabetics about 2% blind because of retinopathy, the patient of about 10% shows as serious vision impairment.Photoreceptor
The Modern medical therapy intervention of cell transition oxidative stress remains a large amount of blank.
Ginsenoside Rb1's compound English is abbreviated as Ginsenoside Rb1, and Chinese chemical name is referred to as ginsenoside
Rb1, its chemical constitution is shown in formula I.Ginsenoside Rd's compound English is abbreviated as Ginsenoside Rd, Chinese chemical name
Referred to as ginsenoside Rd, chemical structural formula is as shown in Formula II.
Photoreceptor cell refers to experience photostimulation, and produces neural impulse and be transmitted to the sensory cell of nervus centralis,
Play extremely important role at external information in the incoming brain processes of visual system, photoreceptor cell includes that retinal rod is thin
Born of the same parents and cone cell, wherein rod cell department scotopic vision, cone cell department vision improvement and epicritic vision.Photoreceptor cell apoptosis
Research confirm, photoreceptor cell is the most fragile, is easily damaged by environment and light source, and it is the neural thin of central nervous system
Born of the same parents, the most impaired, it is impossible to regeneration.Chinese patent 201210228744X, discloses naringenin and is preparing anti-retinal photoreceptor
Application in apoptotic medicine, compound naringenin has protection and makees the photochemical damage of retinal light injury photoreceptor
With, and it is resistant to the apoptosis of retinal light injury photoreceptor, can be used for preparing various resisting apoptosis of a retinal photoreceptor cell medicine.
But, existing document not yet reports that ginsenoside Rb1 and Rd combination are being treated with on photoreceptor cell death, retinal pigment
Skin and photoreceptor cell oxidative stress are the disease of central pathological, become including age-related macular degeneration, retinal pigment
In terms of the Retinal degeneration such as property, Stargardt disease, the cone-rod cell malnutrition, diabetic retinopathy
Pharmacologically active.
Summary of the invention
It is an object of the invention to for deficiency of the prior art, it is provided that a kind of prevention and/or treatment retina degeneration
The pharmaceutical composition of pathological changes.
Another purpose of the present invention is to provide the purposes of pharmaceutical composition described above.
For achieving the above object, the present invention adopts the technical scheme that:
A kind of prevention and/or the pharmaceutical composition for the treatment of Retinal degeneration, described medicine is by following bulk drugs system
Standby form: ginsenoside Rb1, ginsenoside Rd, described ginsenoside Rb1, ginsenoside Rd structural formula respectively such as Formulas I and formula
Shown in II.
As a kind of preferred implementation, described ginsenoside Rb1 and ginsenoside Rd's mass ratio are 26:5-10；
As a kind of preferred implementation, described ginsenoside Rb1 and ginsenoside Rd's mass ratio are 26:9.
As a kind of preferred implementation, described pharmaceutical composition comprises the drug regimen of therapeutically effective amount described above
Thing and pharmaceutically acceptable excipient, carrier or diluent.
As a kind of preferred implementation, described pharmaceutically acceptable carrier includes the additives of ophthalmically acceptable solvent, injection
With additives, tablet additives, surfactant and stabilizer；Described ginsenoside Rb1 and Rd are combined as described medicine group
The main active of compound.
In the present invention, described ginsenoside Rb1 and Rd pharmaceutical composition can be used alone or as active component and its
He is used in mixed way by the adjuvant of routine.
As a kind of preferred implementation, described pharmaceutical composition also includes the medicine of other treatment ocular disease.
For realizing above-mentioned second purpose, the present invention adopts the technical scheme that:
First aspect, it is provided that medicine as above is used for treating and/or preventing Retinal degeneration, described view
Film degeneration is dead as central pathological with retinal light injury photoreceptor, or has retinal pigment epithelium or light sensation
The oxidative stress of receiver cell participates in.
As a kind of preferred implementation, described Retinal degeneration is selected from: age-related macular degeneration,
Stargardt disease, the cone-rod cell malnutrition, retinitis pigmentosa and diabetic retinopathy.
Second aspect, it is provided that pharmaceutical composition purposes in pharmacy or reagent as above, described medicine or reagent
For protecting amphiblestroid form, structure or function.
The third aspect, it is provided that pharmaceutical composition purposes in pharmacy or reagent as above, described medicine or reagent
For suppressing retina photodamage.
Fourth aspect, it is provided that pharmaceutical composition purposes in pharmacy or reagent as above, described medicine or reagent
For:
(1) it is used for preventing or treat retinal light injury photoreceptor dead；
(2) it is used for preventing or treat retinal pigment epithelium or photoreceptor cell over oxidation stress；
(3) it is used for maintaining outer nuclear layer form；
(4) it is used for preventing outer nuclear layer thickness from reducing；
(5) it is used for suppressing retina injury related immune inflammatory reaction.
As a kind of preferred implementation, described pharmaceutical composition is as single component or pharmaceutically acceptable with other
Composition constitutes compositions in order to pharmacy or reagent.
In the present invention, described pharmaceutical composition ginsenoside Rb1 and Rd are that inventor passes through greatly in numerous ginsenosides
Measure experiment screening and obtain, the advantage that the combination of ginsenoside Rb1 and Rd has good drug efficacy, consumption is little.
The invention has the advantages that:
The present invention uses the mouse model of retina photodamage, simulates in multiple Retinal degeneration generating process
Common pathology link, i.e. photoreceptor cell death, retinal pigment epithelium and photoreceptor cell oxidative stress, to people
Ginseng saponin Rb1 and Rd combines anti-light receptor cell retinal pigment epithelium oxidative stress dead, anti-, anti-retina injury
The effect that related immune inflammatory reaction, preventing and treating Retinal degeneration occur is studied, and result shows ginsenoside Rb1
With Rd combination photoreceptor cell mortality, retinal pigment epithelium and photoreceptor cell oxygen to photic damage induction
Change stress, retinal light injury photoreceptor degenerative change and retina injury related immune inflammatory reaction there is significantly suppression
Effect, can significantly treat and improve Retinal degeneration, therefore can be used for preparing treatment and includes that age-related macular becomes
Property, retinitis pigmentosa, Stargardt be sick, the cone-rod cell malnutrition, diabetic retinopathy etc. are interior
Multiple Retinal degeneration medicine.
Accompanying drawing explanation
Accompanying drawing 1 is ginsenoside Rb1 and the Rd combined therapy OCT qualification result to photoreceptor cell protective effect.Its
Middle normal control mice accepts 50 μ l30%DMSO solvent control, and photic damage model mice accepts 50 μ l30%DMSO solvents pair
According to, ginsenoside Rb1 and Rd combination group mice accept 50 μ l ginsenoside Rb1 and Rd combined therapies, ginsenoside Rb1 and Rd agent
Amount is respectively 65mg/kg and 22.5mg/kg body weight, and all treatments all use intraperitoneal injection, in addition to normal control mice, control
Treating latter 30 minutes each group mices and accept white light, illumination condition is 10,000Lux, continues 30 minutes.After illumination 7 days, mice
Mydriasis after 1% pentobarbital sodium anesthesia, uses OCT to carry out retinal structure imaging analysis respectively.No light: normal control,
Do not accept illumination；Light_vehicle: photic damage model；Light_Rb1&Rd: ginsenoside Rb1 and Rd combined therapy and light
According to group.
Accompanying drawing 2 is ginsenoside Rb1 and the quantitative analysis to retina protective effect of the Rd combined therapy, and OCT has analyzed
After, ONL thickness has been carried out quantitative analysis.
Accompanying drawing 3 is ginsenoside Rb1 and the Rd combined therapy histopathological study to retina protective effect.All little
Mus is put to death after 7 days OCT image, and solution takes eyeball, and 4% paraformaldehyde is fixed, and carries out paraffin embedding and section.The stone of 4 μ m-thick
Wax section carries out H&E dyeing.The result of H&E dyeing carries out microscope observation and takes pictures and analyze.
Accompanying drawing 4 is ginsenoside Rb1 and the immunohistochemistry research to retina protective effect of the Rd combined therapy.All
Mice is put to death after 7 days OCT image, and solution takes eyeball, and 4% paraformaldehyde is fixed, and carries out paraffin embedding and section.Take 4 μ m-thick
Paraffin section de-waxing process after carry out Rhodopsin, opsin M and DAPI immunostaining, respectively to rod cell acromere, regard
Cone cellular matrix sheath and nucleus carry out immune labeled.Immunohistochemistry results carries out microscope observation and takes pictures and analyze.
Accompanying drawing 5 is that ginsenoside Rb1 and Rd combine anti-retinal pigment epithelium and photoreceptor cell oxidative stress
Research.Each group mice 1 day difference lumbar injection superoxide anion fluorescent probe DHE after illumination, put to death after 2 hours,
Solution takes eyeball, separates and reject cornea and crystalline lens, and remaining carries out 4% paraformaldehyde containing retina part and fixes, and carries out ice
Freeze embedding and section, the red fluorescence result of the frozen section layer each to retina taking 12 μ m-thick carry out microscope observe take pictures and
Analyze.
Accompanying drawing 6 is the research of the activation hypertrophy of ginsenoside Rb1 and the Rd anti-retina immune inflammation cell of combination.Each group is little
Mus is put to death for 3 days after illumination, and solution takes eyeball respectively, separates and reject cornea and crystalline lens, and remaining is carried out containing retina part
4% paraformaldehyde is fixed, and carries out frost embedding and section, and the frozen section taking 12 μ m-thick carries out GFAP, Iba1 and DAPI immunity
Dyeing, carries out immune labeled to M ü ller glial cell, microglia and nucleus respectively.Immunohistochemistry results enters
Row microscope is observed and is taken pictures and analyze.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate this
Bright rather than limit the scope of the present invention.In addition, it is to be understood that after having read the content that the present invention records, art technology
The present invention can be made various changes or modifications by personnel, and these equivalent form of values fall within the application appended claims equally and limited
Fixed scope.
Term used herein " acceptable ", refers to a prescription component or the active component health to general treatment target
There is no undue adverse effect.
Term used herein " is treated ", including the symptom or the situation that relax, suppress or improve disease；Suppression complication
Produce；Improve or prevent potential metabolic syndrome；Suppression disease or the generation of symptom, as controlled disease or the development of situation；Subtract
Light disease or symptom；Disease or symptom is made to go down；Alleviate the complication caused by disease or symptom, or prevention or treatment are by disease
Or the sign that symptom causes.As used herein, a certain compound or pharmaceutical composition, after administration, a certain disease, symptom can be made
Or situation improved, espespecially its severity is improved, delayed onset, slows down disease progression, or reduces the state of an illness persistent period.
No matter fixing be administered or interim be administered, be administered continuously or interrupted continuous administration, can owing to or the situation relevant with administration.
Term used herein " pharmaceutically acceptable " herein refers to a kind of material, such as carrier or diluent, will not make chemical combination
The biological activity of thing or character disappear, and relative nontoxic, e.g., give individual something, will not cause undesired biotic influence
Or interact with any component that it contains in harmful manner.
Embodiment
In the present embodiment, by retina optical fundus tomoscan OCT technology, pathology and the immuning tissue of Noninvasive
The research means learned, specify that ginsenoside Rb1 and the Rd combination intervention effect to retina photodamage mouse model.Research knot
Fruit shows that ginsenoside Rb1 and Rd combination can effective prevention photoreceptor cell be dead and the generation of Retinal degeneration,
Amphiblestroid structure is played significant protective effect.
One, method
1. medicine
Ginsenoside Rb1 and ginsenoside Rd.Ginsenoside Rb1 is purchased from Yuan Ye bio tech ltd, Shanghai,
41753-43-9, Lot#H02J6X4, purity >=98%.Ginsenoside Rd is purchased from Yuan Ye bio tech ltd, Shanghai,
52705-93-8, Lot#H02J6X2, purity >=98%.
2. animal model
4-6 week old female Balb/c mice (Si Laike, Shanghai) is used to test.Mice is randomly divided into normal control
Group, photic damage model control group, ginsenoside Rb1 and Rd combined treatment, ginsenoside Rb and Rd dosage be respectively 65mg/kg and
22.5mg/kg body weight, first 30 minutes lumbar injections of illumination.Light stimulation will use the disperse cold fluorescent lamp of white, and illumination condition sets
It is set to 10,000Lux, continues 30 minutes.After illumination 7 days, carry out retinal morphology analysis respectively.
3. retinal structure analysis
After Drug therapy and illumination the 7th day, 1% pentobarbital sodium anesthetized mice, after tropicamide mydriasis, use toy
Each group of Mouse Retina form is observed and compares by OCT (Phoenix Research Labs) respectively.
4.ONL thickness measurement is analyzed
After OCT image, from ONH, (the papilla of optic nerve), between to inner side and outside retina ONL thickness with 500 μm being
Away from measuring, the effect of each group of retinal structure protection is carried out quantitative analysis.
5. retinal tissue pathology
After OCT image 7 days, put to death mice, take eyeball, fix with 4% paraformaldehyde.Fixing eyeball tissue carries out stone
Wax embedding and slicing treatment.Paraffin section thickness is 4 μm, dyes and immunohistochemical staining for further H&E, including
Rhodopsin labelling cone cell, opsin M labelling rod cell, DAPI carries out nuclear marker.After illumination 3 days, put to death
Mice, takes eyeball, rejects cornea and crystalline lens, will contain amphiblestroid eyeball tissue and fix with 4% paraformaldehyde under microscope.Gu
Fixed eyeball tissue carries out frozen section process.Frozen tissue section thickness is 12 μm, for further immunohistochemistry
Dyeing, including GFAP labelling M ü ller glial cell, Iba1 labelling microglia, DAPI carries out nuclear marker.
6. in-situ oxidation stress level is analyzed
After Drug therapy and illumination 1 day, each group mice lumbar injection superoxide anion fluorescent probe DHE respectively, 2 is little
Time put to death mice, take eyeball, separate and reject cornea and crystalline lens, retina part will be contained and carry out 4% paraformaldehyde and fix.
Fixing eyeball tissue carries out frozen section process, and frozen tissue section thickness is 12 μm, each for analyzing retina further
The red fluorescence of layer.
7. statistical analysis
Data representation is means ± S.E, and data analysis uses indepedent sample t test method.p<0.05
It is defined as statistically-significant difference.
Two, result
1. white light induction Mouse Retina seriously damages
After white light 7 days, use OCT that retinal structure is carried out imaging.As it is shown in figure 1, white light induction is serious
With the retina degenerative change that photoreceptor cell damage is main pathological manifestations, mainly show as after white light 7 days
ONL major injury.
2. ginsenoside Rb1 and Rd combine retina protective effect
First 30 minutes of white light, mice accepts solvent or ginsenoside Rb1 and Rd combined therapy, ginsenoside Rb1 and
Rd dosage is respectively 65mg/kg and 22.5mg/kg body weight, and volume is 50 μ l, lumbar injection.After illumination 7 days, OCT is used to carry out
Retinal structure is analyzed.As it is shown in figure 1, ginsenoside Rb1 and Rd combined therapy all significantly suppress sending out of retina photodamage
Raw, mainly show as ONL form and remain intact, the quantitative analytical data (Fig. 2) of ONL thickness is shown, and do not accept illumination
Normal mouse retina compares, and illumination causes retina ONL thickness seriously to reduce (* p < 0.05), and ginsenoside Rb1 and Rd
Combined therapy serves significantly protection to retina ONL, its each ONL thickness close to the normal mouse view not accepting illumination
(* photic damage model group compares film ONL thickness with Normal group, p < 0.05；# ginsenoside Rb1 and Rd combine and photic damage mould
Type group compares, p < 0.05).Histopathological study result (Fig. 3) shows, does not accepts normal mouse retina each layer knot of illumination
Structure is complete, and photic damage mice shows as ONL and seriously reduces, and the retina of ginsenoside Rb1 and Rd combined therapy group mice is each
Rotating fields is to not accept light group similar.Further immunohistochemistry result of study (Fig. 4) shows, the ONL of DAPI labelling
At photic damage Mouse Retina serious loss, compared with normal control, the rarely seen remaining expression of Rhodopsin, opsin M (* p <
0.05).Ginsenoside Rb1 and Rd combined therapy group Rhodopsin, opsin M expression pattern are similar to Normal group, ONL
Have no substantially damage (Rhodopsin: red, opsin M: red, DAPI: blue).Superoxide anion silver light is used to visit
Pin DHE carries out in-situ oxidation stress level analysis, as it is shown in figure 5, do not accept each layer of normal control mice retina of illumination not
Seeing red fluorescent, be obviously enhanced seen from the retinal pigment epithelium (RPE) of photic damage Mouse Retina and ONL is red
Color fluorescence signal, ginsenoside Rb1 and Rd combined therapy group mice are only at red fluorescent faint seen from RPE.GFAP marks
Note M ü ller glial cell is mainly expressed at nerve fibre layer (Fig. 6), photic damage model in the normal control mice of non-illumination
Mouse Retina then shows as ONL, IPL and INL all has obvious GFAP to express, ginsenoside Rb1 and Rd combined therapy group
GFAP expression pattern is similar to Normal group；The microglia of Iba1 labelling is mainly expressed at normal mouse retina
At ONL, OPL, the retina of IPL (Fig. 6) photic damage model is all shown in that substantial amounts of positive Iba1 expresses, and ginsenoside Rb1 and Rd group
The Iba1 expression pattern closing treatment group is similar to Normal group.
In sum, by using OCT iconography and retinal histopathology means to retina photodamage model
Research prompting ginsenoside Rb1 and Rd combination death, retinal pigment epithelium and light to retinal light injury photoreceptor
The Retinal degeneration that receptor cell oxidative stress, retina injury related immune inflammatory reaction extremely cause has
There is significant preventive and therapeutic effect.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of without departing from the inventive method, it is also possible to makes some improvement and supplements, and these improve and supplement and also should be regarded as
Protection scope of the present invention.
Claims (10)
1. a prevention and/or the pharmaceutical composition for the treatment of Retinal degeneration, it is characterised in that described medicine is by following
Crude drug is prepared from: ginsenoside Rb1, ginsenoside Rd；Described ginsenoside Rb1, the structural formula difference of ginsenoside Rd
As shown in Formulas I and Formula II；
Prevent and/or treat the pharmaceutical composition of Retinal degeneration the most according to claim 1, it is characterised in that
Described medicine is prepared from by following bulk drugs: ginsenoside Rb1, ginsenoside Rd, described ginsenoside Rb1 and ginsenoside
Rd mass ratio is 26:5-10；Or described ginsenoside Rb1 is 26:9 with ginsenoside Rd's mass ratio.
Prevent and/or treat the pharmaceutical composition of Retinal degeneration the most according to claim 1, it is characterised in that
Described pharmaceutical composition comprises the pharmaceutical composition described in claim 1-2 of therapeutically effective amount and pharmaceutically acceptable
Excipient, carrier or diluent；Described pharmaceutically acceptable carrier include the additives of ophthalmically acceptable solvent, injection additives,
Tablet additives, surfactant and stabilizer；Described ginsenoside Rb1 and Rd are combined as the main of described pharmaceutical composition
Active component.
Prevent and/or treat the pharmaceutical composition of Retinal degeneration the most according to claim 1, it is characterised in that
Described pharmaceutical composition also includes the medicine of other treatment ocular disease.
5. claim 1-4 arbitrary described pharmaceutical composition purposes in pharmacy, it is characterised in that described medicine is used for controlling
Treating and/or prevention Retinal degeneration, described Retinal degeneration is to be with retinal light injury photoreceptor death
Central pathological, or have the oxidative stress of retinal pigment epithelium or photoreceptor cell to participate in.
Purposes the most according to claim 5, it is characterised in that described Retinal degeneration is selected from: age related
Degeneration of macula, Stargardt disease, the cone-rod cell malnutrition, retinitis pigmentosa and diabetic retinopathy.
7. claim 1-4 arbitrary described pharmaceutical composition purposes in pharmacy or reagent, it is characterised in that described medicine
Or reagent is used for protecting amphiblestroid form, structure or function.
8. claim 1-4 arbitrary described pharmaceutical composition purposes in pharmacy or reagent, it is characterised in that described medicine
Or reagent is used for suppressing retina photodamage.
9. claim 1-4 arbitrary described pharmaceutical composition purposes in pharmacy or reagent, it is characterised in that described medicine
Or reagent is used for:
(1) it is used for preventing or treat retinal light injury photoreceptor dead；
(2) it is used for preventing or treat retinal pigment epithelium or photoreceptor cell over oxidation stress；
(3) it is used for maintaining outer nuclear layer form；
(4) it is used for preventing outer nuclear layer thickness from reducing；
(5) it is used for suppressing retina injury related immune inflammatory reaction.
10. according to the purposes described in claim 5-9, it is characterised in that described pharmaceutical composition as single component or and its
His pharmaceutically acceptable composition constitutes compositions in order to pharmacy or reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610494685.9A CN106074585B (en) | 2016-06-29 | 2016-06-29 | Ginsenoside Rb1 and Rd combination and its application in the drug of preparation treatment photoreceptor cell death related disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610494685.9A CN106074585B (en) | 2016-06-29 | 2016-06-29 | Ginsenoside Rb1 and Rd combination and its application in the drug of preparation treatment photoreceptor cell death related disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106074585A true CN106074585A (en) | 2016-11-09 |
| CN106074585B CN106074585B (en) | 2019-01-11 |
Family
ID=57214581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610494685.9A Active CN106074585B (en) | 2016-06-29 | 2016-06-29 | Ginsenoside Rb1 and Rd combination and its application in the drug of preparation treatment photoreceptor cell death related disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074585B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111187330A (en) * | 2020-01-10 | 2020-05-22 | 天津中医药大学 | Triterpenoid saponin component with anti-photodamage activity in folium Notoginseng |
| WO2020199460A1 (en) | 2019-04-04 | 2020-10-08 | 北京诚毅投资股份有限公司 | Use of luteolin-7-o-glucoside or luteolin-7-o-glucuronide in preparation of medicine for eye injuries |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173358A (en) * | 2014-08-27 | 2014-12-03 | 哈尔滨珍宝制药有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
-
2016
- 2016-06-29 CN CN201610494685.9A patent/CN106074585B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173358A (en) * | 2014-08-27 | 2014-12-03 | 哈尔滨珍宝制药有限公司 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Non-Patent Citations (2)
| Title |
|---|
| 段元青等: "血塞通对糖尿病视网膜病变患者眼底微循环及血流动力学的影响", 《山东医药》 * |
| 雄海伟等: "超滤工艺对血塞通注射液中有效成分的影响研究", 《中药材》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020199460A1 (en) | 2019-04-04 | 2020-10-08 | 北京诚毅投资股份有限公司 | Use of luteolin-7-o-glucoside or luteolin-7-o-glucuronide in preparation of medicine for eye injuries |
| CN111187330A (en) * | 2020-01-10 | 2020-05-22 | 天津中医药大学 | Triterpenoid saponin component with anti-photodamage activity in folium Notoginseng |
| CN111187330B (en) * | 2020-01-10 | 2022-01-11 | 天津中医药大学 | Triterpenoid saponin component with anti-photodamage activity in folium Notoginseng |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106074585B (en) | 2019-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harocopos et al. | Importance of vitreous liquefaction in age-related cataract | |
| WO2022194109A1 (en) | Complex for treating optic nerve disease, and preparation method therefor and use thereof | |
| CN103933058B (en) | The application of luteolin-7-glucosulfone aldehydic acid glycosides in preparation treatment Retinal degeneration medicine | |
| Sakai et al. | The ability of hyperoxia to limit the effects of experimental detachment in cone-dominated retina | |
| US8097640B2 (en) | Prophylactic or therapeutic agent for diabetic maculopathy | |
| Schuettauf et al. | Administration of novel dyes for intraocular surgery: an in vivo toxicity animal study | |
| Kizawa et al. | Effects of anthocyanin, astaxanthin, and lutein on eye functions: a randomized, double-blind, placebo-controlled study | |
| Shi et al. | Colored floaters as a manifestation of digoxin toxicity | |
| Wei et al. | Melatonin regulates traumatic optic neuropathy via targeting autophagy. | |
| CN106074585A (en) | Ginsenoside Rb1 and Rd combination and preparation treatment photoreceptor cell death relevant disease medicine in application | |
| CN105343107A (en) | Application of tripterine to preparation of medicine treating degenerative retinopathy related diseases | |
| KR102099520B1 (en) | Chinese medicine composition to treat diabetic retinopathy | |
| Yu | Pharmacological correction of morphofunctional retinal injury using 11-amino acid fragment of darbepoetin in the experiment | |
| Pinilla et al. | Retinal sensitivity in patients with type I diabetes without retinopathy or with minor retinal changes | |
| Sithole | A review of the use of Streptozotocin (STZ) in the induction of diabetes in rats and subsequent ocular tissue changes | |
| CN101584686A (en) | Application of sodium valproate during preparing medicament for treating retina disease | |
| Kaldırım et al. | Efficacy of hyperbaric oxygen therapy on central corneal thickness, intraocular pressure, and nerve fiber layer in patients with type 2 diabetes: A prospective cohort study | |
| Nian et al. | Protecting the Aging Retina | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| Klimo et al. | Structure and function of retinal ganglion cells in subjects with a history of repeated traumatic brain injury | |
| Yavuz Saricay et al. | Can Nerve Growth Factor (NGF) Be a Treatment Option for Pediatric Eye Diseases? | |
| Jiang et al. | Biomechanical analysis of optic nerve injury treated by compound light granules and ciliary neurotrophic factor☆ | |
| CN112057490A (en) | Application of chrysanthemum rice extract in preparing medicine for preventing and treating diabetic retinopathy | |
| CN113350326B (en) | Application of compound LM22B-10 in preparation of corneal epithelium and nerve injury treatment drugs | |
| CN103933057B (en) | The application of clerodendrin in preparation treatment Retinal degeneration medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |